UCB and UK’s MRC Technology have entered an exclusive license agreement under which UCB will obtain rights to an undisclosed fibrosis therapy program. The program resulted from MRC’s collaboration with the University of Sheffield on the development of a novel antibody-based therapy targeting the progression of fibrosis. Additional terms were not disclosed.   MRC Technology will receive an upfront payment, clinical development milestones and royalties on future product sales. In accordance with t...